Biopharmx Corp (NYSE:BPMX) major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the firm’s stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total value of $59,278.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of Biopharmx Corp (NYSE:BPMX) opened at $0.19 on Tuesday. Biopharmx Corp has a 1-year low of $0.16 and a 1-year high of $0.90.
Biopharmx Corp (NYSE:BPMX) last released its earnings results on Wednesday, September 13th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.06). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Biopharmx Corp had a negative return on equity of 5,749.08% and a negative net margin of 22,005.88%.
ILLEGAL ACTIVITY WARNING: This story was first posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.truebluetribune.com/2017/11/14/biopharmx-corp-bpmx-major-shareholder-vivo-capital-viii-llc-sells-296394-shares.html.
A number of analysts have recently issued reports on BPMX shares. Maxim Group reduced their target price on Biopharmx Corp from $3.00 to $1.50 and set a “buy” rating for the company in a report on Wednesday, September 13th. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Biopharmx Corp in a report on Wednesday, September 13th.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.